MRUS250117C22500
- 0.00
- 0.000.00%
Merus Newsroom
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
Canaccord Genuity Sticks to Its Buy Rating for Merus (MRUS)
BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $73
BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Announces Target Price $73
Promising Potential of Merus's Petosemtamab in HNSCC: A Buy Recommendation
A Quick Look at Today's Ratings for Merus(MRUS.US), With a Forecast Between $67 to $97
Merus Analyst Ratings
Merus Is Maintained at Buy by Citigroup
Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and C4 Therapeutics (CCCC)
Analysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Arcellx Inc (ACLX)
Truist Financial Maintains Merus(MRUS.US) With Buy Rating
TD Cowen Maintains Merus(MRUS.US) With Buy Rating
Truist Financial Sticks to Its Buy Rating for Merus (MRUS)
Needham Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $85
Merus's Promising Prospects: Buy Rating Highlighted by Positive Data on Peto's Efficacy in HNSCC
Merus Price Target Maintained With a $85.00/Share by Needham
Merus Analyst Ratings
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100
A Quick Look at Today's Ratings for Merus(MRUS.US), With a Forecast Between $67 to $85
Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), Larimar Therapeutics (LRMR) and Merus (MRUS)